Tag-assisted peptide synthesis TAPS is a liquid-phase method that uses a soluble tag to isolate the growing peptide after each coupling step. This guide explains how the tagging mechanism works, compares TAPS with solid-phase and classical solution-phase peptide synthesis, and reviews what the…
Tag-assisted peptide synthesis TAPS is a liquid-phase route to peptides that borrows the central trick of solid-phase chemistry. A soluble tag is covalently attached to the growing chain so that after each coupling step the product can be separated from excess reagents and byproducts by precipitation, filtration, or extraction instead of by chromatography. A peptide developer chooses TAPS over solid-phase peptide synthesis SPPS for three practical reasons: it scales more readily, it consumes less solvent and fewer reagents, and it produces high-purity peptides in the short-to-medium length range. Those advantages are real in mechanism but documented mainly in vendor material, so this guide separates what is established from what is claimed.
The technical guide on which this article's vendor claims rest was published on 15 July 2026 by Bachem, a peptide manufacturer that offers TAPS within its development and manufacturing services. The guide counts four main methods for creating peptides but names only three: classical liquid-phase peptide synthesis LPPS , TAPS, and SPPS. The fourth method is never identified. Bachem's claims about TAPS are vendor claims, not independent findings; where the published literature bears on the question, it is cited below.
TAPS is a special variant of LPPS. In classical solution-phase synthesis, the peptide grows in homogeneous solution and every intermediate must be purified by extraction, crystallization, or chromatography, because nothing separates the product from unreacted materials. SPPS solved that problem by anchoring the chain to an insoluble resin bead: filtration and washing remove everything not attached to the resin. TAPS occupies the middle ground. The chain stays in solution, where coupling kinetics are homogeneous, but a deliberately designed tag makes the product separable by a simple phase change.
Historically, TAPS was used mainly for shorter peptides, because it offered less control over each synthesis step than SPPS. Without a solid support, every separation depends on the tag's solubility behavior being exactly right, and a precipitation that is not quantitative in one cycle contaminates the next. Tag design and process understanding have since matured, and the method has attracted interest as a platform technology. The interest is driven by scalability and by reduced use of reagents and solvents, the same factors that make any liquid-phase process attractive to manufacturers.
Choosing the tag is the critical decision, and it is the practical bottleneck. A useful tag must dissolve in the organic solvents used for coupling and deprotection, remain distinct from all other materials in the reaction so that it can be cleanly removed, survive the coupling and deprotection chemistry, and carry a linker that can be cleaved at the end without damaging the peptide. The guide does not disclose which tag chemistries are used, and no tag structures appear in the peer-reviewed sources cited here. That matters because the tag determines the entire solvent and workup system, which in turn determines yield, purity, and cost.
TAPS runs as a repeating cycle that mirrors SPPS. The first amino acid is attached through a cleavable linker to the tag. The N-terminus is then deprotected and coupled to the next activated amino acid in an organic solvent. Because the tag keeps the growing peptide in solution, the coupling is a homogeneous reaction: the activated ester and the free amine meet in free solution rather than inside a resin bead. Homogeneous kinetics are the mechanistic basis for the guide's claims of efficient peptide bond formation and improved yields on custom sequences, though those claims are vendor-reported and not independently quantified.
At the end of each coupling, the mixture is treated to switch the solubility of the tagged peptide. Adding a non-solvent, changing solvent polarity, or exploiting a temperature-dependent solubility difference makes the tag-peptide conjugate precipitate while excess activated amino acid, coupling byproducts, and deprotection agents stay dissolved. The solid is collected by filtration or centrifugation, washed, and redissolved for the next cycle. This one operation replaces the repeated resin washes of SPPS. The tag is thus directly analogous to the solid support: it is the handle that makes separation possible, with the difference that it is soluble during the reaction and insoluble during the workup.
The tag also fixes what classical LPPS cannot. As a chain grows, its solubility drifts with amino acid composition, and intermediates become progressively harder to handle. A well-designed tag dominates the solubility of the conjugate, so the growing peptide behaves predictably from cycle to cycle, until the chain becomes long enough that the peptide's own character overrides the tag. That is the practical origin of the short-to-medium length window in which TAPS is described as delivering high purity and reliable results.
After the final coupling, the tag and the side-chain protecting groups are removed. Final purification is still generally needed, as it is after SPPS, because precipitation separates the tagged product from reagents but does not remove truncated or epimerized byproducts from the full-length chain. The historical weakness of TAPS, less step-to-step control than SPPS, is exactly the risk that a workup that is not quantitative will let failures accumulate.
The Bachem guide compares three primary methods: LPPS, TAPS, and SPPS. Their operating principles and reported characteristics are summarized below.
| Method | Support | Separation after each coupling | Solvent and reagent load | Length strength | Main limitation |
|---|---|---|---|---|---|
| LPPS | None | Extraction, crystallization, or chromatography | Moderate | Short | Solubility and byproduct removal degrade as the chain grows |
| TAPS | Soluble tag | Precipitation, filtration, or extraction | Claimed low; no published figures | Short to medium | Tag design is a bottleneck; historically less step-to-step control |
| SPPS | Insoluble resin | Filtration and resin washes | High | Short to medium, with automation extending the range | Large volumes of hazardous solvent; difficult long or complex sequences |
SPPS attaches the growing chain to an insoluble resin support, which makes it easy to wash away excess reagents and byproducts. It is fast and efficient for high-throughput work and for shorter peptides, and the guide describes it as the go-to method for large-scale production. Its costs are structural: SPPS uses significant amounts of hazardous reagents and solvents, and it struggles with longer or more complex peptides. Automation has pushed the length ceiling higher, but the solvent burden remains: every coupling and wash cycle consumes many resin-bed volumes of solvent.
Classical LPPS is cost-effective, scalable, and relatively environmentally friendly, but it encounters difficulties with longer peptides as reaction consistency, solubility, and byproduct removal all deteriorate. Against SPPS, the guide claims that TAPS is also cost-effective and scalable, and more environmentally friendly, because it requires fewer reagents and substantially less solvent, reducing organic waste. No quantitative comparison is supplied, so the environmental claim reads as a directional advantage rather than a measured one.
The honest summary: TAPS keeps the scalability of solution chemistry, fixes the isolation problem that limits LPPS, but pays for that with the requirement of a validated tag and a less mature control record than SPPS.
The peer-reviewed record on TAPS itself is thin. No head-to-head study of TAPS versus SPPS, no quantitative solvent accounting, and no disclosed tag chemistries appear in the indexed literature cited here. What the literature does establish is the surrounding physics: the length limits of stepwise methods, the automation-driven extension of SPPS, and the existence of alternative reduced-waste chemistries.
A 2022 review of hybrid peptide synthesis notes that polymerization methods for alpha/beta-peptides and peptide/peptoid hybrids can produce high-molecular-weight polymers cheaply and simply, unlike solution and solid-phase methods, which generally give defined-sequence oligomers PMID 35978269 . This is a useful boundary condition. TAPS, as a variant of solution-phase chemistry, belongs to the oligomer class, so its short-to-medium window is not a marketing choice but a chemical characteristic shared by all stepwise methods.
The other boundary is moving. Automated peptide synthesizers, aided by advances in chemistry, can now produce peptides exceeding 150 amino acid residues, which has aided glycoprotein synthesis PMID 35601548 . That qualifies the claim that SPPS struggles with longer peptides: at research scale, automation has pushed solid-phase synthesis far beyond the short-to-medium range. For a developer choosing between TAPS and SPPS, the length argument cuts both ways. TAPS is competitive in the short-to-medium window, while SPPS has a documented path to very long chains, at least for sequences that behave well.
For short peptides in particular, SPPS is exceptionally well tooled. A 1995 methods paper showed that multiple peptide synthesis can produce many short peptides at microgram-to-milligram scale, including libraries with millions of sequences, though these approaches are less suitable for very long peptides or high-purity needs PMID 7552694 . A 2024 report extended that approach: by modifying an automated synthesizer to use 384-well plates, the authors produced 1,536 short peptides in a single run, with an average yield of 0.5 μmol, an average concentration of 10 mM, and an average purity of about 80% without purification PMID 38220145 . This is the comparison that matters for discovery-stage work. If the goal is many short candidates, automated parallel SPPS is fast, established, and cheap; TAPS does not compete on that axis.
On the waste side, TAPS is not the only attempt to reduce the reagent and solvent burden of stepwise synthesis. A 2021 paper described biphasic electrochemical peptide synthesis in which triphenylphosphine is oxidized to act as the coupling reagent, generating recyclable triphenylphosphine oxide, and the authors successfully synthesized leuprorelin without conventional coupling reagents PMID 34745521 . Leuprorelin is a short clinical peptide, squarely in the short-to-medium window where TAPS claims its strengths. The paper demonstrates that reduced-waste synthesis is being pursued from several directions and that the short-to-medium range is where most new chemistry is first shown to work.
Taken together, the published record supports the claims that conventional solution-phase and solid-phase hybrid-peptide methods generally give defined-sequence oligomers PMID 35978269 , that SPPS is powerful for short peptides PMID 38220145 and is being extended toward long ones by automation PMID 35601548 , and that reduced-reagent coupling chemistry is feasible for short clinical peptides PMID 34745521 . It does not independently establish the specific claims that TAPS uses much less solvent, improves yields on custom sequences, or is more environmentally friendly than SPPS. Those are vendor assertions, plausible in mechanism but unquantified in the public domain.
Consider TAPS when the target is a short-to-medium peptide, a single sequence or a small panel rather than thousands of analogs, and when the goal is scale-up with purity, yield, and reduced solvent waste as priorities. That is the window in which the method is described as delivering high purity and reliable results, and where homogeneous solution conditions can improve yields on difficult custom sequences and reduce costs.
Tag selection comes first. Choose a soluble tag that dissolves in organic solvents and can be cleanly separated from the reaction mixture; tag choice drives overall efficiency. In practical terms, verify the tag's solubility switch against the planned solvent system before committing to the synthesis, confirm that the linker is cleavable under conditions compatible with the sequence, and ask for batch data on per-step yields and epimerization before trusting purity claims.
Do not choose TAPS for every problem. If the need is many parallel short peptides, automated SPPS has the documented track record, including 1,536 peptides in one run at about 80% average purity without purification PMID 38220145 , and library-scale production PMID 7552694 . If the target exceeds 150 residues, automated SPPS is the method with a published path PMID 35601548 , and for high-molecular-weight polymers, polymerization routes beat both solution and solid-phase stepwise methods PMID 35978269 .
Evaluate TAPS as an alternative, not a replacement. SPPS remains the default method for many pharmaceutical applications. A buyer evaluating a TAPS offer should ask for the tag chemistry, the step-by-step reaction and isolation conditions, a quantitative solvent and reagent balance per kilogram of peptide, and a comparison against the SPPS route carried out on the actual sequence. In the absence of published numbers, a pilot comparison on the specific peptide is the only reliable test of the claims.
On the supplier side, Bachem offers TAPS within a service portfolio that covers process development and analytical support across clinical phases, and states that its GMP-compliant facilities are routinely inspected by regulators including the FDA and Swissmedic. That statement describes Bachem's own operations; it says nothing about whether TAPS outperforms SPPS, and a buyer should verify regulatory status directly.
The central caveat is provenance. The fullest public description of TAPS is a vendor guide, and its presentation of the method's benefits is promotional in nature. The guide asserts that Bachem has 50 years of experience moving peptide breakthroughs from discovery to commercialization; that is corporate branding, not a technical finding, and it does not bear on whether TAPS performs as described.
The practical specifics a developer would need are mostly absent. The guide does not disclose the tag chemistries used, the step-by-step reaction and isolation conditions, or the quantitative reductions in reagent and solvent use that TAPS achieves. Its section promising a detailed look at the process does not in fact enumerate the steps. How TAPS handles longer or more complex peptides in practice is unestablished, as is its behavior when scaled from laboratory synthesis to commercial manufacturing. The tag must satisfy stringent solubility and separation requirements, and the guide does not say how often tag redesign is needed when a sequence misbehaves.
The source itself acknowledges that TAPS historically offered less control over each synthesis step than SPPS. Nothing in the public record quantifies the improvement that tag chemistry advances have delivered on that front. Until independent studies report per-step yields, racemization, and failure accumulation for realistic sequences, the control gap remains an open question.
Two inconsistencies in the source matter for anyone reading it carefully. The guide says LPPS is one of four main methods for creating peptides but names only three, leaving the fourth unspecified. And the characterization of TAPS as the most environmentally friendly and sustainable option is framed as a marketing advantage, not a measured result. Fewer reagents and less solvent are directional statements; comparative life-cycle data are not in the public domain.
The bottom line: TAPS is a mechanically sound idea. A soluble handle that switches solubility between reaction and workup is a real answer to the isolation problem that has always limited classical solution-phase synthesis, and the scaling and waste advantages over SPPS are credible in principle. The evidence base, however, is vendor-driven and short on numbers. For a researcher or buyer working with short-to-medium custom peptides and weighing scale-up, purity, and environmental metrics, TAPS warrants a pilot evaluation on the actual sequence, with the tag chemistry, per-step yields, solvent balance, and waste streams placed on the table before any commitment.
Peptides referenced: Leuprolide.
Vendors referenced: Purity Peptides.
Related reading: Synthesizing Peptides Over 100 Amino Acids: Methods and Examples, API Contract Manufacturing: Process, Benefits, and Partner Selection, Manual Fmoc Solid-Phase Peptide Synthesis: A Beginner's Protocol, Peptide CoA: What HPLC Purity and LC-MS Actually Prove.